34.75 USD
↘ 0.78 (2.20%)AT CLOSE (03:59 PM EDT)
Roivant Sciences Ltd. Common Shares
ROIVNASDAQ • USD
34.91
↗ 0.16 (0.45%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
34.91
↗ 0.16 (0.45%)
Market: CLOSED
Roivant Sciences Ltd. Common Shares (ROIV) trades at $34.76 per share. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Oct 7, 2026.
Open?$35.22
High?$35.49
Low?$34.63
Prev. Close?$35.53
Volume?5.7M
Avg. Volume?9.0M
VWAP?$35.10
Rel. Volume?0.64x
Bid / Ask
Bid?$33.15 × 100
Ask?$36.91 × 100
Spread?$3.76
Midpoint?$35.03
Valuation & Ratios
Market Cap?25.7B
Shares Out?722.3M
Float?371.0M
Float %?51.8%
P/E Ratio?N/A
P/B Ratio?6.07
EPS?-$0.37
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees
721
Market Cap
25.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-10-01
Address
7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
Phone: 441-295-5950
LONDON, SW1H 0DB
Phone: 441-295-5950
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?35
Piotroski F-Score?0/9Weak
Altman Z-Score?40.44Safe
Confidence?58%Low
Short InterestElevated
Short % of Float?9.75%Elevated
Short Interest?36.2M
Days to Cover?4.1
Free Float371.0M
Avg Daily Volume8.8M
Settlement Date2026-09-15
Financial Health
Current Ratio?16.72Strong
Quick Ratio?16.72Strong
Cash Ratio?4.40Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?6.07FAIR▾
Peers100
S&P30
P/S?3,407.35HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-17.9CHEAP▾
S&P97
EV/Sales?3,241.59HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-6.3%WEAK▾
S&P10
ROA?-5.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-821063000
Enterprise Value?$24.4B
Fundamentals ratios updated end of day